Product nameAnti-C4a antibody [EPR11241]
See all C4a primary antibodies
DescriptionRabbit monoclonal [EPR11241] to C4a
Tested applicationsSuitable for: WB, Flow Cytmore details
Unsuitable for: ICC/IF,IHC or IP
Species reactivityReacts with: Human
Recombinant fragment within Human C4a. The exact sequence is proprietary.
Database link: P0C0L4
- Human angioneoplasm lysate, HepG2 cells.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab170917 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/5000. Predicted molecular weight: 193 kDa.|
|Flow Cyt||1/100 - 1/500.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
FunctionC4 plays a central role in the activation of the classical pathway of the complement system. It is processed by activated C1 which removes from the alpha chain the C4a anaphylatoxin. The remaining alpha chain fragment C4b is the major activation product and is an essential subunit of the C3 convertase (C4b2a) and the C5 convertase (C3bC4b2a) enzymes of the classical complement pathway.
Derived from proteolytic degradation of complement C4, C4a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
Involvement in diseaseDefects in C4A are the cause of complement component 4A deficiency (C4AD) [MIM:120810]. A rare defect of the complement classical pathway associated with the development of autoimmune disorders, mainly systemic lupus with or without associated glomerulonephritis.
Sequence similaritiesContains 1 anaphylatoxin-like domain.
Contains 1 NTR domain.
modificationsPrior to secretion, the single-chain precursor is enzymatically cleaved to yield the non-identical chains (alpha, beta and gamma). During activation, the alpha chain is cleaved by C1 into C4a and C4b, and C4b stays linked to the beta and gamma chains. Further degradation of C4b by C1 into the inactive fragments C4c and C4d blocks the generation of C3 convertase.
N- and O-glycosylated. O-glycosylated with a core 1 or possibly core 8 glycan.
- Information by UniProt
- Acidic complement C4 antibody
- C3 and PZP like alpha 2 macroglobulin domain containing protein 2 antibody
- C3 and PZP-like alpha-2-macroglobulin domain-containing protein 2 antibody
Flow cytometric analysis of permeabilized HepG2 cells labeling C4a with ab170917 at 1/100 (red) or a rabbit IgG negative (green).
All lanes : Anti-C4a antibody [EPR11241] (ab170917) at 1/1000 dilution
Lane 1 : Human angioneoplasm lysate
Lane 2 : HepG2 cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat ant-rabbit HRP conjugated antibody at 1/2000 dilution
Developed using the ECL technique.
Predicted band size: 193 kDa
ab170917 has not yet been referenced specifically in any publications.